Gyre Therapeutics, Inc. (GYRE) · Oct 22, 2026 · Exec change

Gyre CEO Ying Luo signs employment deal, with no leadership change

CEO employment formalized — Ying Luo remains CEO; $500,000 base salary and $150,000 2026 bonus target

Gyre’s CEO employment agreement formalizes pay and severance terms, but adds no new executive or operating milestone.

Gyre is a commercial-stage biopharmaceutical company expanding beyond its China-based fibrosis franchise into a broader pipeline through Cullgen, while advancing F351 toward potential approval for chronic-hepatitis-B-related liver fibrosis. Ying Luo was already publicly identified as President and CEO before this filing, so the agreement does not alter the company’s operating leadership or pipeline direction.

This is a formalization, not a leadership event. The agreement confirms that Ying Luo will continue serving as CEO. 〔0〕 Because her CEO role was already public, the filing mainly documents the employment relationship rather than revealing a surprise management change.

The agreement sets standard executive economics and downside protection. It provides a $500,000 annual base salary and a $150,000 target bonus for 2026. 〔1〕 Outside a change-in-control period, termination without cause would trigger six months of base salary, continued COBRA support for up to 12 months, and acceleration of equity that would have vested over the following year. During a change-in-control period, the cash severance expands to base salary plus the target bonus, with full equity vesting.

The business impact is minimal. These terms create a defined retention and severance framework while Gyre works through its Cullgen integration and F351 regulatory path, but they do not provide a new financing, clinical result, approval, or guidance change. The agreement also supersedes prior employment or change-in-control arrangements, so the main new information is the precise contractual package rather than a change in strategy.

Bottom line: This is routine executive documentation for an already announced CEO, not a new catalyst. It clarifies compensation and termination protections but barely changes Gyre’s underlying business story.

Original filing on SEC EDGAR

Gyre CEO Ying Luo signs employment deal, with no leadership change | GYRE Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.